Affordable Vital Signals Monitor Care Support System(VSMCSS)

According the WHO 100 million people still pushed into extreme poverty because of health expenses.

According to the NIH the 3 factors that affect access to healthcare include poverty, geographic area of residence, race and ethnicity, sex, age, language spoken, and disability status.

The OECD Health Statistics 2022   Preliminary estimates for a group of 17 OECD countries suggest that health spending continued to grow strongly in 2021 – by around 6%.

We aim to make health care available, timely ,convenient, and affordable by automatizing the vital signals monitor of preventive affection data management.

As the main cost comes from the specialized personnel remuneration, a great opportunity area on cost reduction becomes evident from the automation of the patient’s vital signs monitoring.

Healthcare cost rise as illness progress from the preventive to the damage stage.

For this reason, a preventive vital signs monitor can reduce health care cost by monitoring, controlling and evaluating patient’s health to produce individual health insights at the preventive stage.

As you can see at the folder 10. Preventive Monitor VSMCSS

https://home.mycloud.com/action/share/f63678ff-9e37-4912-ae39-dbe357708161

We would like to remind that due the confidentiality the  information of the link remains confidential and is “For Solve Use Only”. It should not be used on any public setting.

“For Solve Use Only”

What it is?

Vital Signals Monitor Care Support System (VSMCSS) is conformed by a set of biomedical sensors that collect patient’s data, an algorithm that analyzes this data, and a database from which insights are generated.

What does it do?

It massively gathers health information from individuals who want monitor their health condition on a regular basis during a preventive stage of illness (pre-diabetes, hypertension, lung function, heart distress).

The insights generation is then processed to accurately identify anomalies and emitting recommendations which then are shared to specialist to take preventive or corrective action.

With the implementation of Big Data analysis, an upper level of insights is created in order to supply National Health Care Systems to generate public health policies.

It completely replaces the pulmonary function named “Hematosis” consisting on the interchange of oxygen from the venous blood.

In simple terms, it helps people to breathe without employing their lungs.

What processes and technology does it use?

• Noninvasive measurements.
• Algorithm analysis.
• Big Data
• Redundancy
• Cloud storage.

How does it incorporate inclusive human-centered design?

We consider inclusive human-centered design through Accessibility (making it accessible for people with disabilities, easy reachable no invasive sensors), Togetherness (sensor that fits everyone: children, seniors, skinny, obese, short, tall people), Language (considering several languages: Spanish, English, German, French, Portuguese, Chinese however the principal will be considered at first stages), Fluid interfaces (Friendly user interface), Automation (Reducing activities, and actions that the patient must perform.), Controls (Poka-Yoke unambiguous controls), Customization (User interface customization), Safety (People with disabilities children, seniors),

How is it better and/or complementary to existing methods in low- and middle-income countries?

From many years, public health systems in low/middle income countries have been under distress due the lack of funding, personnel and resources. By focusing on massively reducing cost through automation, we can reduce the cost burden from low income families and the public health system to bring proper preventive health care to more people.

Moreover, the cost of corrective health care is higher at the correction/damage stage than at the prevention stage. Let’s take as example the hypertension. Poor blood pressure monitoring brings renal and liver failures which treatment besides costly is life threatening.

Who is collecting your primary health care data?

Personal health care date is extremely sensitive and its collection, safeguarding must attend to regulation, account with patient’s approval for handling and processing.

The data will be collected on a private Cloud Storage System to be shared possibly with Health Care Authorities or private institutions in accordance with the permissions granted by the patients.

Feel free to review photographic evidence at link. https://home.mycloud.com/action/share/f63678ff-9e37-4912-ae39-dbe357708161

We would like to remind that due the confidentiality the project requires all the information of the link remains confidential and is “For Solve Use Only”. It should not be used on any public setting.

“For Solve Use Only”

Target population whose lives you are working to directly and meaningfully improve. 

Patients with diabetes, hypertension, cardiovascular diseases, lung affections and obesity.

According the WHO[1] The number of people with diabetes rose from 108 million in 1980 to 422 million in 2014. Prevalence has been rising more rapidly in low- and middle-income countries than in high-income countries.

Diabetes is a major cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation.

Between 2000 and 2016, there was a 5% increase in premature mortality from diabetes.

In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes.

A healthy diet, regular physical activity, maintaining a normal body weight and avoiding tobacco use are ways to prevent or delay the onset of type 2 diabetes.

Diabetes can be treated and its consequences avoided or delayed with diet, physical activity, medication and regular screening and treatment for complications.

According to the National Diabetes Statistics Report from the CDC [2] in the US alone there are 37.3 million people have diabetes (11.3% of the US population) from which 28.7 million people, are diagnosed and 8.5 million people (23.0% of adults) are undiagnosed, 96 million people aged 18 years or older have prediabetes (38.0% of the adult US population)

According to a recent national health survey (M Phillips 1, J Salmerón[3]), the prevalence of self-reported diabetes in Mexico is 1.2%, but this figure reflects the relative youth of the Mexican population. Age-specific estimates are similar to those for the United States of America, where crude prevalence is higher. Given that self-reporting usually underestimates prevalence by at least 50%, there may be as many as 1.7 million persons with diabetes in Mexico, with a prevalence of approximately 6% in the age range 30-64 years. The average age at death for Mexicans with diabetes is 57 years, compared to 69 years for the population as a whole. Diabetes is the fifth most important cause of death in the Mexican population, and the third cause in people over 45 years of age, in whom it accounts for 10% of all deaths. There is evidence for important increases in diabetes-related mortality over time. Most studies indicate high rates of complications in Mexicans with diabetes and data show that their average length of hospital stay is almost twice as long as for non-diabetic patients. The annual cost of diabetes to Mexican society may be estimated at US$ 15 million for metabolic control, US$ 85 million for additional health services and US$ 330 million for indirect costs--in total, approximately three-quarters of all government spending on health care, or approximately US$ 450 per known diabetic person per year.

High Blood Pressure

According the WHO[4] Hypertension  ̶  or elevated blood pressure  ̶  is a serious medical condition that significantly increases the risks of heart, brain, kidney and other diseases.

An estimated 1.28 billion adults aged 30-79 years worldwide have hypertension, most (two-thirds) living in low- and middle-income countries

An estimated 46% of adults with hypertension are unaware that they have the condition.

Less than half of adults (42%) with hypertension are diagnosed and treated.

Approximately 1 in 5 adults (21%) with hypertension have it under control.

Hypertension is a major cause of premature death worldwide.

One of the global targets for noncommunicable diseases is to reduce the prevalence of hypertension by 33% between 2010 and 2030.

Cardiovascular diseases (CVDs)

Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year (WHO[5]).

The most important behavioral risk factors of heart disease and stroke are unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. The effects of behavioral risk factors may show up in individuals as raised blood pressure and overweight and obesity among others. These “intermediate risks factors” can be measured in primary care facilities and indicate an increased risk of heart attack, stroke, heart failure and other complications.

Lung affections & COVID-19

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. (WHO[6])

Nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries (LMIC).

Early diagnosis and treatment, including smoking cessation support, is needed to slow the progression of symptoms and reduce flare-ups.

Obesity

Some recent WHO[7] global estimates:

In 2016, more than 1.9 billion adults aged 18 years and older were overweight. Of these over 650 million adults were obese.

In 2016, 39% of adults aged 18 years and over (39% of men and 40% of women) were overweight.

Overall, about 13% of the world’s adult population (11% of men and 15% of women) were obese in 2016.

The worldwide prevalence of obesity nearly tripled between 1975 and 2016.

Who are they, and in what ways are they currently underserved?

All people from the middle and low class whom has not the culture, nor the resources to procure and/or access health care services disregarding their age, sex and any other condition.

The data will be collected from noninvasive methods which will allow to focus on diseases which the main causes of death due lack of monitoring/prevention: diabetes, high blood pressure, Cardiovascular diseases (CVDs), lung affections.

How will the solution address their needs?

An automated data collection device like the VSNCSS will gather information from noninvasive sensors (which will allow their reusability and cost reduction) to gather data from blood pressure, weight, oxygenation and others to determine the actual condition of the patient. In this way, though and algorithm it will evaluate the associated health risk for diabetes, hypertension, lung disease and will inform the patient and/or to specialized care personnel to take preventive or corrective action.

Having broad information about the patient or group of patients, insights can be synthetized from data to considering on public health care policy making.

[1] https://www.who.int/news-room/...

[2] https://www.cdc.gov/diabetes/d...

[3] https://pubmed.ncbi.nlm.nih.go...

[4] https://www.who.int/news-room/...

[5] https://www.who.int/health-top...

[6] https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

[7] https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight#:~:text=Facts%20about%20overweight%20and%20obesity&text=In%202016%2C%2039%25%20of%20adults,tripled%20between%201975%20and%202016.

“For Solve Use Only”

Why you and your team are the right people to design and deliver this solution to the target population?

Having a strong medical doctor’s team, allow us to clearly understand and assess patient’s needs, difficulties and concerns regarding their health issues.

Master on Sciences Luis Martínez has been working 8 years as CEO at Proyección 22 leveraging the company from a startup to a main actor on research & development on Mexico from which the Science & Technology National Council has requested external consultancy

He has developed collaboration agreements with more than 16 universities all around Mexico to reach, develop and boost talent from scientific minded students

This allow us to conform a with leaders on the specific areas from engineering like electronics, mechatronics, systems, clinical and medical doctors.

We would like to understand your proximity to the communities you are serving. In particular, how are you and your team representative of these communities?

Proyección 22 has secured more than $431,131 USD in funding from the Ernest Solvay Fund, managed by the King Baudouin Foundation, the National Entrepreneur Fund and the Science & Technology National Council.

M.Sc. Luis Martínez has leveraged Proyección 22 from a startup to a main actor on R&D in Mexico from which the Science & Technology National Council has requested advisory during the pandemic where he was acknowledged as one of the main experts on the field nationwide.

Recently he was awarded by the King Baudouin Foundation through the Ernest Solvay Fund to encourage young scientific talent in the region to develop high impact technological solutions and drive professional development on mechatronics, electronics and programing and preventing them to join drug cartels as a way of living.

Based on the previous statements, Proyección 22 can deliver proper proof of its commitment and involvement with the community no just in the medical and technical aspects, but also in the social and equality too.

What are you doing to understand the needs of those you’re serving, and how are you engaging them as you develop the solution?

To properly understand the needs of diabetes, hypertension and hypoxemia we constantly are in communication with our group of specialist like our double specialist in internal medicine, endocrinology and diabetes Dr. Carlos Amezcua who brings world class research methodologies as he has conducted research protocols in the Mayo Clinic at Rochester Minnesota, the Diabetes Research Institute at Miami, Florida in USA and in the High Specialization Medic Centers “La Raza” and “Siglo XXI” at México City.

His social spirit has focused on working to boost the health quality for low income communities in both in United States for Latin American migrant communities and in Mexico for the prevention, correction and treatment for diabetes.

His specializations are on internal medicine with a sub specialization on endocrinology graduating as best of his class.

Dr. Carlos Amezcua was awarded "Young Scientist Endocrine Society Award 2012", recognition given to some of the best talents on the field worldwide.

Also Dr. José A. Melgoza is a board member who performed as CEO of the largest Specialties Hospital on the City “Hospital de Especialidades El Ángel”. He has specializations on Orthopedics and Traumatology. He was the founder of the Orthopedics & Traumatology Society in the State and became its president.  Now he is retired and works as an advisor at the Proyección 22 board assessing organizational performance and enhancing the organization networking. He is profoundly convinced that medical treatment must be economically reachable for low income families and actively advocates among medical community to support poor families.

How is the design and implementation of your solution meaningfully guided by the communities’ input, ideas, and agendas?

Cartels violence in our community has truncated the professional career development from scientific minded students whom had fled due the excessive violence.

Thanks to the King Baudouing Fundation Support we will bring back those students and by promoting high tech complex project we will open a professional development path.

We are confident that by helping them we will be helping us, students will engage with initiatives, will commit with community needs and will tackle world’s biggest challenges

We would like to remind that due the confidentiality the project requires all the information of the link remains confidential and is “For Solve Use Only”. It should not be used on any public setting.

1. We want to join this challenge to apply the funding for the consolidation of a research facility and boost scientific activities as a way to stablish a career path for young scientific minded students as a way to prevent them from joining the drug cartels as a way of living.

1. At the same time, by implementing high demanding technological challenges, we aim to reduce talent migration and impulse local entrepreneurship as a path to increase local competitiveness.
2. In this way we will be able to combat local cartel’s violence with science and technological projects that in the long term, will reconstruct the social fabric, so badly damaged by the actual regional violence.
3. We are in the path of success thanks to the collaboration with 16+ universities nationwide and the recent support from the King Baudouin Foundation through the Ernest Solvay Fund.

“For Solve Use Only”

New or significantly improved approach to the problem.

By consensus of the medical community, most of the corrective stage illnesses could have been prevented if were properly detected at their early stages.

However, there is not a culture of prevention, nor enough resources properly allocated and distributed in the public health sector to gather, manage and analyze patient’s clinical data.

Expertise is scarce, not always properly trained and susceptible to human error.

There is a great opportunity of cost reduction, massive deployment and service level increase by automating the proposed process.

How it could be catalytic: do you expect it to change the market or enable broader positive impacts from others in this space?

It will be catalytic in terms of reducing preventive medicine available for the middle and low income families, reducing not just the cost for the public sector but reducing the risks associated with the deterioration of the health level that brings families to a extreme poverty situation according the WHO.

Feel free to review evidence at the 10. Preventive Monitor VSMCSS folder in the next link.

https://home.mycloud.com/action/share/f63678ff-9e37-4912-ae39-dbe357708161

We would like to remind that due the confidentiality the project requires all the information of the link remains confidential and is “For Solve Use Only”. It should not be used on any public setting.

Next year:

• We aim to prepare a protocol for test on humans as a requirement for the humans’ trial FDA. COFEPRIS,EMA approval.
• To have successfully performed the sensors trials test.
• To enhance our facilities for next stages of testing.

Next five years:

• We aim to be already deploying our service, in Latin America, USA, UK, Europe and Australia.

“For Solve Use Only”

There are many factors we are considering in order to properly asses our progress and achieve our goals.

The technology indicator:

The measurement is based on the Technology Readiness Level developed by the NASA.

The finance indicator:

It is based on the amount on funding we are securing.

So far we have been granted with $431,131 USD in funding from the King Baudouin Foundation through the Ernest Solvay Fund, the National Entrepreneur Fund and the Science & Technology National Council.

Feel free to review evidence at the next link.

https://home.mycloud.com/action/share/f63678ff-9e37-4912-ae39-dbe357708161

We would like to remind that due the confidentiality the project requires all the information of the link remains confidential and is “For Solve Use Only”. It should not be used on any public setting.

Synergies indicator:

It is based on the number of institutions internationally with whom we have signed a collaboration agreement.

Talent reach indicator:

It is based on the number of talented, scientific minded students and/or professionals we are able to reach.

All these indicators are based on a strategy for securing proper execution which is based on the Balanced Score Card.

1. Funding and synergies securing

By securing funding and establishing synergies in USA and Europe we expect to allow not just the continuation of the device development but to start gaining traction for future venture capital investors. 
By generating synergies with the medical sector we expect to gain access to the expertise for procuring the sanitary authority approval and allow an international deployment.

2. Facilities enhancement
For us, a social impact on the community is not optional but a MUST!.  Regional violence is degrading social fabric making scientific talent to flee to pursue better opportunities nationally or internationally.
By establishing a research facility and enhancing our prototyping, testing and innovation capabilities we will be able to attract, develop and retain scientific minded talent and secure a career path development as a way reconstruct the social fabric, boosting local entrepreneurship and increasing regional competiveness.

3. International collaboration agreements expansion
From our interaction with professor Eric Verhoogen from Columbia University, to reach the level of scientific excellence we are aiming, stablishing international collaboration is the next step. We expect to increase our expertise level, deepen our international regulatory knowledge and enhance universities collaboration agreements to transmit high level know-how to local students.

4. Project activities breakdown universities distribution
With the collaboration of nationwide universities, a Work breakdown Structure will allow to distribute activities packages among specialized groups under a project oriented management structure. Based on this strategy we will be able to spur innovation.

5. Iteration rate increasing
Innovations and improvements will increase if the facilities and collaborations build a value chain to integrate prototypes modifications in a fast pace. We expect to reduce the time to market by increasing the iteration rate.

6. Device integration and testing
As part of the TRL maturation process and the iteration rate increase the integration and testing will allow us to strengthen the device reliability and performance in order to ensure approvals from sanitary authorities like COFEPRIS in México, FDA in USA, EMA in Europe, the ANMATM in Argentina  and the ANVS in Brazil.

“For Solve Use Only”

In combination with the sensors, the core of the technology relies on the data selection algorithm which discriminate data against two main heuristics, the first based on patient’s historic data and the second based on derivations of present data values change. In combination both values allow to project, under predefined limit values, if the patient’s data is increasing its standard deviation not from the average or mean from literature but from a personalized, tuned up value according his/her personal biological characteristics. This will allow to data-cross values against historic records and diagnose imperceptible changes to asses a proper preventive or corrective action.

Some examples are the biomass index, the hearth rate and the oximetry values.

The biomass index is calculated based on a predefined body type but for each patient it must be considered for his/her specific body type (ectomorph, mesomorph and endomorph). This aspect has great relevance when it comes to diabetes diagnosis and treatment. An endomorph person will always have a high biomass index but it doesn’t he/she has obesity.

When it comes to hearth rate, not all abnormal frequencies are of concern, nor all normal frequencies should not be of concern but patients are unaware allowing the evolution of the illness to a corrective stage which could be fatal.

Lastly, oximetry normal values highly depend on the person’s age, physical activity and skin color as oximeters are calibrated to only measure certain wavelengths from which the reflectance or transmittance can be severely affected from the mentioned factors. During the COVID19 the lack of proper oximeters may have had an impact on a poor patient’s oxygen administration.

We would like to remind that due the confidentiality the project requires all the information of the link and presented on the solver platform remains confidential and is “For Solve Use Only”. It should not be used on any public setting.

The data will be collected for the company from noninvasive methods which will allow to focus on diseases which the main causes of death due lack of monitoring/prevention: diabetes, high blood pressure, Cardiovascular diseases (CVDs), lung affections.

The collection incentive is to generate recommendations to the patients’ health habits to prevent them to develop severe illness.

In order to promote DEI, we are against people being labelled in any way. We are people! We are all the same! and must be treated equally.

Everybody is treated as a person, no more nor less, a person with all its dignity and value.

We select our team in terms of their moral values, their capabilities, and their commitment.

As long as a person has moral values and a will to make a social impact, he/she is more than welcome in our team.

“For Solve Use Only.”

Based on the CANVAS framework:

Value proposition:

Our value proposition consists on an automated affordable service for monitoring vital signs on a regular basis for low and middle income families in countries where public health systems are under strain due the lack of funding, resources or personnel.

Segments (key customers and beneficiaries):

All people from the middle and low class whom has not the culture, nor the resources to procure and/or access health care services disregarding their age, sex and any other condition.

Patients with pre-diabetes or diabetes

According the WHO[1] The number of people with diabetes rose from 108 million in 1980 to 422 million in 2014. Prevalence has been rising more rapidly in low- and middle-income countries than in high-income countries.

Diabetes is a major cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation.

Patients with High Blood Pressure

According the WHO[2] Hypertension  ̶  or elevated blood pressure  ̶  is a serious medical condition that significantly increases the risks of heart, brain, kidney and other diseases.

An estimated 1.28 billion adults aged 30-79 years worldwide have hypertension, most (two-thirds) living in low- and middle-income countries

Patients with Lung affections & COVID-19

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. (WHO[3])

Nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries (LMIC).

Patients with Obesity

Some recent WHO[4] global estimates:

In 2016, more than 1.9 billion adults aged 18 years and older were overweight. Of these over 650 million adults were obese.

In 2016, 39% of adults aged 18 years and over (39% of men and 40% of women) were overweight.

Overall, about 13% of the world’s adult population (11% of men and 15% of women) were obese in 2016.

The worldwide prevalence of obesity nearly tripled between 1975 and 2016.

Impact:

We mainly aim to reduce the strain on the public health systems from low and middle income countries by automating the preventive monitoring diagnostics through noninvasive sensors to reduce costs from specialized personnel and cost from illness progression.

Revenue:

It is expected it will generate a 21% revenue per device at a cost of 4.5 USD per patient considering 15 mins per patient, 10 hours a day, 30 days a month and a downtime at nights a flow of 1200 patients a month or 14,400 a year will generate

Channels

There are two main channels for service distribution. The private channel service will be paied directly by the patient. The public channel service will be paid through government as a rent.

Intervention

Consist on an automated self-service.

Key activities

Securing availability of devices. Training proper use. Providing maintenance. Monitoring performance. Disposal of used supplies.

Key resources

Procuring 24/7 technical support. Securing sufficient stock of replacement materials.

Partners

Hospitals and medical personnel, insurances, suppliers.

Cost structure

Preventive and corrective maintenance. Technicians, physicians training. Procurement logistics and machine distribution. Overheads. Supplies manufacturing.

[1] https://www.who.int/news-room/...

[2] https://www.who.int/news-room/...

[3] https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

[4] https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight#:~:text=Facts%20about%20overweight%20and%20obesity&text=In%202016%2C%2039%25%20of%20adults,tripled%20between%201975%20and%202016.

“For Solve Use Only.”

Grant stage:

To reach the development of these devices we have been awarded with $431,131 USD in funding from the King Baudouin Foundation through the Ernest Solvay Fund, the National Entrepreneur Fund and the Science & Technology National Council.

Seed capital stages:

Main channel of revenue will come from capital investors.

Venture Capital stage:

Once the technology has reached its maturity, the revenue streams will come from the private sector through contracts with multinational insurance companies; and to from the public sector, through public health contracts with federal governments to serve high specialization hospitals.

Revenue generating stage:

It is expected it will generate a 21% revenue per device at a cost of 4.5 USD per patient considering 15 mins per patient, 10 hours a day, 30 days a month and a downtime at nights a flow of 1200 patients a month or 14,400 a year will generate 

“For Solve Use Only.”

At this stage:

To reach the development of these devices we have been awarded with $431,131 USD in funding from the King Baudouin Foundation through the Ernest Solvay Fund, the National Entrepreneur Fund and the Science & Technology National Council.

Feel free to review evidence at the 0. Previous funding folder & King Baudouin folder, in the next link. We would like to remind that due the confidentiality the project requires all the information of the link remains confidential and is “For Solve Use Only”. It should not be used on any public setting.

https://home.mycloud.com/action/share/f63678ff-9e37-4912-ae39-dbe357708161

At the next stage:

Once the device has reached enough TRL maturity our focus will move to secure capital investment, internationalization and high medical/tech talent through seed capital, equity interchange etc.

We are being advised by Abeona Capital and began conversations with the Wellcome Fund a specialized UK fund for bioengineering research.

This funding will allow us to begin human trials.

Finally, at the third stage:

We will be advised by the previous incorporated funds to reach mayor investment firms, request FDA and EMA approval for market growth in South America and Europe to provide service to low income families.